S
SQ INNOVATION LTD.
SQ Innovation is a privately-held Swiss biopharmaceutical company located in Zug, Switzerland, and Burlington, MA, that was established to develop and commercialize innovative cost-effective therapies for subcutaneous delivery of pharmaceutical products where and when needed. Its first product, for the treatment of fluid overload (edema) in patients with heart failure, is currently under development following a plan that has been reviewed with the US-FDA. The novel combination product is based on the Sensile Medical micro-pump technology and its small-volume cartridge-based platform. The device design uses a reusable motorized component and disposable cartridge, which minimizes waste and creates cost-effective treatment options in numerous therapy areas, including treatment of edema in heart failure. The products are subject to regulatory review and approval.
Company Email ：info@sqinnovation.com
Industry ：Hospitals & ClinicsHealthcare
Company address ：20 Mall Rd Ste 220, Burlington, Massachusetts, 01803, United States
Company website ：*****
Company phone ：(781) 552-4990
Established ：-
Company Revenue ：$3,921,000
Number of employees ：<25
SIC Code ：8028
NAICS Code ：32325
Main Products ：ResultsEffective Treatment at HomeHealthcare Funding is TightThoughtful Design
Web Summary
Q1: What is the address of SQ Innovation Ltd.'s offices?
A1: SQ Innovation has offices in Canton Zug, Switzerland, and Burlington, Massachusetts, U.S., with the specific address being 20 Burlington Mall Road, Suite 220 Burlington, MA 01803, USA.
Q2: What is the name of the company's product for heart failure treatment?
A2: The company's product is called Lasix ONYU, which is a novel drug formulation and subcutaneous Infusor to deliver hospital-strength diuresis for at-home use.
Q3: In what year did Lasix (furosemide) first get introduced in the market?
A3: Lasix (furosemide) was first introduced in the 1960s, and has been the leading diuretic for heart failure patients for over 50 years.
Q4: What is unique about SQ Innovation's approach to treating heart failure patients with Lasix ONYU?
A4: SQ Innovation's approach is to make subcutaneous drug delivery more convenient, comfortable, affordable, and widely accessible, using a novel drug formulation and a subcutaneous Infusor that can administer an 80mg therapeutic dose in a significantly smaller volume.
Q5: What is the Tentative FDA Approval status of Lasix ONYU?
A5: Lasix ONYU has received Tentative FDA Approval in October 2024, but it has not yet been approved for sale.
Q6: How does SQ Innovation's subcutaneous Infusor work?
A6: The Infusor is designed to deliver hospital-strength diuresis for at-home use, and can be recharged and used for 48 treatments, with the only thing being thrown away being the single-use component.
Q7: Who are the good candidates for using SQ Innovation's subcutaneous treatment?
A7: Good candidates are hard to define, but it is easier to determine what patients and circumstances are unsuitable. Timing is critical, and clinicians need to evaluate the patient and environment to determine if subcutaneous treatment is a good option.
Q8: What is the environmental impact of SQ Innovation's subcutaneous Infusor?
A8: The Infusor creates a new option for providing "IV-strength" diuresis outside an acute care setting, which markedly reduces cost and is better for the environment.
A1: SQ Innovation has offices in Canton Zug, Switzerland, and Burlington, Massachusetts, U.S., with the specific address being 20 Burlington Mall Road, Suite 220 Burlington, MA 01803, USA.
Q2: What is the name of the company's product for heart failure treatment?
A2: The company's product is called Lasix ONYU, which is a novel drug formulation and subcutaneous Infusor to deliver hospital-strength diuresis for at-home use.
Q3: In what year did Lasix (furosemide) first get introduced in the market?
A3: Lasix (furosemide) was first introduced in the 1960s, and has been the leading diuretic for heart failure patients for over 50 years.
Q4: What is unique about SQ Innovation's approach to treating heart failure patients with Lasix ONYU?
A4: SQ Innovation's approach is to make subcutaneous drug delivery more convenient, comfortable, affordable, and widely accessible, using a novel drug formulation and a subcutaneous Infusor that can administer an 80mg therapeutic dose in a significantly smaller volume.
Q5: What is the Tentative FDA Approval status of Lasix ONYU?
A5: Lasix ONYU has received Tentative FDA Approval in October 2024, but it has not yet been approved for sale.
Q6: How does SQ Innovation's subcutaneous Infusor work?
A6: The Infusor is designed to deliver hospital-strength diuresis for at-home use, and can be recharged and used for 48 treatments, with the only thing being thrown away being the single-use component.
Q7: Who are the good candidates for using SQ Innovation's subcutaneous treatment?
A7: Good candidates are hard to define, but it is easier to determine what patients and circumstances are unsuitable. Timing is critical, and clinicians need to evaluate the patient and environment to determine if subcutaneous treatment is a good option.
Q8: What is the environmental impact of SQ Innovation's subcutaneous Infusor?
A8: The Infusor creates a new option for providing "IV-strength" diuresis outside an acute care setting, which markedly reduces cost and is better for the environment.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
